¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѽÅÀåÇÐȸ KSN-IAC(Integrated Academic Conference) 2023 ÅëÇÕÇмú´ëȸ(1ÀÏÂ÷) : 2023-09-22

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇѽÅÀåÇÐȸ KSN-IAC(Integrated Academic Conference) 2023 ÅëÇÕÇмú´ëȸ(1ÀÏÂ÷) : 2023-09-22
±³À°ÀÏÀÚ : 2023-09-22
±³À°Àå¼Ò : ´ë±¸, ¿¢½ºÄÚ

±³À°ÁÖÁ¦ : KSN-IAC(Integrated Academic Conference) 2023 ÅëÇÕÇмú´ëȸ(1ÀÏÂ÷)

ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
´ã´çÀÚ : ´ëÇѽÅÀåÇÐȸ
¿¬¶ôó : 02-3486-8736  

À̸ÞÀÏ : ksn@ksn.or.kr

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀÎ : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ´ë±¸±¤¿ª½Ã
±³À°½Ã°£ : 22 ½Ã°£ 0ºÐ

¼¼ºÎ¼ö°­·á : 60,000¿ø  

ºñ°í "[»çÀüµî·Ï]¡á Àü¹®ÀÇ(±³¼ö,ºÀÁ÷ÀÇ,°³¿øÀÇ): 1ÀÏ-20,000/ÀüÀÏ50,000 ¡á ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç,¾à»ç,¿µ¾ç»ç,»çȸº¹Áö»ç,ÀÇ·á°ü·ÃÁ¾»çÀÚ: 1ÀÏ-10,000¿ø/ÀüÀÏ-20,000¿ø 

[ÇöÀåµî·Ï]¡á Àü¹®ÀÇ(±³¼ö,ºÀÁ÷ÀÇ,°³¿øÀÇ): 1ÀÏ-30,000/ÀüÀÏ60,000 ¡á ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç,¾à»ç,¿µ¾ç»ç,»çȸº¹Áö»ç,ÀÇ·á°ü·ÃÁ¾»çÀÚ: 1ÀÏ-15,000¿ø/ÀüÀÏ-30,000¿ø *¸¸65¼¼ÀÌ»óȸ¿ø, Çлý-¸éÁ¦"  


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 09¿ù 22ÀÏ Room1 09:00~09:25 Incidence and Characteristics of Renal Cell Carcinoma in ADPKD patients ¹ÚÇýÀÎÁ¶(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room1 09:25~09:50 Recent updates in tolvaptan treatment based on the guidelines ±è¿¹¸²(°è¸íÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room1 09:50~10:15 Efficacy and Safety of Tolvaptan for Patients With Autosomal Dominant Polycystic Kidney Disease in Real-world Practice Á¤¿¬¼ø(°í½ÅÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room1 10:15~10:40 ADPKD ȯÀÚ¿¡¼­ ¿µ¾ç°ü¸® ¿ÀÀ±±Ô(¼­¿ïÀÇ´ë)

Åä·Ð 09¿ù 22ÀÏ Room1 10:40~10:50 ÁúÀÇ ÀÀ´ä ()

ÈÞ½Ä 09¿ù 22ÀÏ Room1 10:50~11:00 ÈÞ½Ä ()

±³À°½Ã°£ 09¿ù 22ÀÏ Room1 11:00~11:20 Tolvaptan in children with ADPKD or ARPKD Á¶¹ÎÇö(°æºÏÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room1 11:20~11:40 Nephrogenic DI or other hyponatremic condition ¼­Áø¼ø(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room1 11:40~12:00 ENT manifestations of Alport syndrome ÀÌ»ó¿¬(¼­¿ïÀÇ´ë )

±³À°½Ã°£ 09¿ù 22ÀÏ Room1 12:00~12:20 Ophthalmologic manifestations of Alport syndrome Á¤ÀçÈ£(¼­¿ïÀÇ´ë )

Åä·Ð 09¿ù 22ÀÏ Room1 12:20~12:50 ÁúÀÇ ÀÀ´ä ()

½Ä»ç 09¿ù 22ÀÏ Room1 12:50~13:50 ½Ä»ç ()

±³À°½Ã°£ 09¿ù 22ÀÏ Room1 13:50~14:15 Nutrition & muscle wasting in patients with AKI undergoing CRRT ±è¿ìÁ¤(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room1 14:15~14:40 Protein diet & muscle wasting in patients with CKD °í°­Áö(°í·ÁÀÇ´ë)

Åä·Ð 09¿ù 22ÀÏ Room1 14:40~14:45 ÁúÀÇ ÀÀ´ä ()

±³À°½Ã°£ 09¿ù 22ÀÏ Room1 14:45~15:10 Mitochondrial dysfunction & Sarcopenia ÀüÀçÇÑ(°æºÏÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room1 15:10~15:35 Gut-muscle crosstalk in CKD Â÷¶õÈñ(±¹¸³ÀÇ·á¿ø)

Åä·Ð 09¿ù 22ÀÏ Room1 15:35~15:40 ÁúÀÇ ÀÀ´ä ()

ÈÞ½Ä 09¿ù 22ÀÏ Room1 15:40~15:50 ÈÞ½Ä ()

±³À°½Ã°£ 09¿ù 22ÀÏ Room1 15:50~16:15 Open label, randomized comparative multicenter clinical trial on the clinical effect of online education program in patient with chronic kidney disease Á¤¹®°æ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room1 16:15~16:40 Adaptive nutrition intervention stabilizes serum phosphorus levels in hemodialysis patients: a multi-center decentralized clinical trial using real-world data ±è°æ¹Î(À»ÁöÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room1 16:40~17:05 The current and future landscape of hemodialysis data management °û»óÇõ(°û»óÇõ³»°ú)

±³À°½Ã°£ 09¿ù 22ÀÏ Room1 17:05~17:30 Smart contract-enabled decentralized clinical research for hemodialysis patients ±èÁÖÇÑ(¼­¿ïÀÇ´ë)

Åä·Ð 09¿ù 22ÀÏ Room1 17:30~17:40 ÁúÀÇ ÀÀ´ä ()

±³À°½Ã°£ 09¿ù 22ÀÏ Room2 09:00~09:25 Understanding roles of thin limbs of the kidney Çѱâȯ(ÀÌÈ­ÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room2 09:25~09:50 Circadian regulation of renal sodium handling ¹ÝÅÂÇö(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room2 09:50~10:10 Mornining vs. evening dosing of antihypertensive medications ¼­»óÇå(Àü³²ÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room2 10:10~10:30 Discontinuing renin-angiotensin system blockades in advanced chronic kidney disease ¹é¼±ÇÏ(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room2 10:30~10:50 Chlorthalidone vs. hydrochlorothiazide on cardiovascular and renal outcomes ¹èÀºÁø(°æ»óÀÇ´ë)

ÈÞ½Ä 09¿ù 22ÀÏ 10:50~11:00 ÈÞ½Ä ()

±³À°½Ã°£ 09¿ù 22ÀÏ Room2 11:00~11:20 Pathophysiology in anemia among AKI patients ¾ÈÁ¤³²(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room2 11:20~11:40 Considerations in therapeutic strategy in anemia of AKI patients ¾çÁöÇö(¼º±Õ°üÀÇ´ë)

Åä·Ð 09¿ù 22ÀÏ Room2 11:40~11:55 ÆгÎÅäÀÇ ÀÌÁ¤È¯, ±èµµÇü, ÀÌÇØ°æ(¼­¿ïÀÇ´ë, ÇѸ²ÀÇ´ë, ¼øõÇâÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room2 11:55~12:15 Pros in HIF-PHD stabilizer among CKD patients ȲÇö¼®(°æÈñÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room2 12:15~12:35 Cons in HIF-PHD stabilizer among CKD pateints ±èÁöÀº(°í·ÁÀÇ´ë)

Åä·Ð 09¿ù 22ÀÏ Room2 12:35~12:50 ÆгÎÅäÀÇ ÀÌÁ¤Ç¥, À±ÇØ·æ, ¾È½Å¿µ(¼­¿ïÀÇ´ë, ¿¬¼¼ÀÇ´ë, °í·ÁÀÇ´ë)

½Ä»ç 09¿ù 22ÀÏ 12:50~13:50 ½Ä»ç ()

±³À°½Ã°£ 09¿ù 22ÀÏ Room2 13:50~14:15 Åõ¼® Àü ¸¸¼ºÄáÆϺ´ ȯÀÚÀÇ ºóÇ÷ °ü¸® À±¿µ¹Î(Á¶¼±ÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room2 14:15~14:40 Ç÷¾×Åõ¼®ÀÌ ¿¹»óµÇ´Â ȯÀÚÀÇ Åõ¼® Á¢±Ù·Î È®º¸ ÀÌÇÏÀº(ÀüÁÖ¿¹¼öº´¿ø)

±³À°½Ã°£ 09¿ù 22ÀÏ Room2 14:40~15:05 Åõ¼® Àü ¸¸¼ºÄáÆϺ´ ȯÀÚÀÇ ½ÄÀÌ °ü¸® ¿°ÁöÇö(ÀüºÏÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room2 15:05~15:30 Åõ¼®Àü ¸¸¼ºÄáÆϺ´ ȯÀÚÀÇ ¾à¹°Ä¡·áÀÇ ÃÖ½ÅÁö°ß Á¤Á¾È¯(¿ø±¤ÀÇ´ë)

Åä·Ð 09¿ù 22ÀÏ Room2 15:30~15:40 ÁúÀÇ ÀÀ´ä ()

ÈÞ½Ä 09¿ù 22ÀÏ 15:40~15:50 ÈÞ½Ä ()

±³À°½Ã°£ 09¿ù 22ÀÏ Room2 15:50~16:10 Optimal Management of CKD-MBD, Focusing on the New Iron-based Phosphate Binder Ȳ¼±´ö(ÀÎÇÏÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room2 16:10~16:30 New Therapeutic Agent for IgA Nephropathy: Nefecon (targeted-release formulation-budesonide) ±èÂùÈ£(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room2 16:30~16:50 The Use of Anti-BAFF Therapy in Kidney Diseases ¹ÎÁö¿ø(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room2 16:50~17:10 Novel Therapies for Alport Syndrome À½»óÈÆ(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room2 17:10~17:30 Mitochondrial Targeted Antioxidants as a Complementary Treatment Strategy À¯º´Ã¶(¼øõÇâÀÇ´ë)

Åä·Ð 09¿ù 22ÀÏ Room2 17:30~17:40 ÁúÀÇ ÀÀ´ä ()

±³À°½Ã°£ 09¿ù 22ÀÏ Room3 09:00~09:25 Role of the calcium-sensing receptor & FGF receptor in CKD-MBD ¾È½Å¿µ(°í·ÁÀÇ´ë)

Åä·Ð 09¿ù 22ÀÏ Room3 09:25~09:30 ÁúÀÇ ÀÀ´ä ()

±³À°½Ã°£ 09¿ù 22ÀÏ Room3 09:30~09:50 Role of the vitamin D receptor in CKD-MBD ±èÁöÀº(°í·ÁÀÇ´ë)

Åä·Ð 09¿ù 22ÀÏ Room3 09:50~09:55 ÁúÀÇ ÀÀ´ä ()

±³À°½Ã°£ 09¿ù 22ÀÏ Room3 09:55~10:15 Role of the type 2 sodium-dependent phosphate cotransporters in CKD-MBD ±èÀ±¹Ì(ºÎ»ê¹éº´¿ø)

Åä·Ð 09¿ù 22ÀÏ Room3 10:15~10:20 ÁúÀÇ ÀÀ´ä ()

±³À°½Ã°£ 09¿ù 22ÀÏ Room3 10:20~10:45 Role of the RANK/RANKL/OPG and Wnt/¥â‑Catenin Systems in CKD-MBD ¾È¼ºÈñ(ÀÎÇÏÀÇ´ë)

Åä·Ð 09¿ù 22ÀÏ Room3 10:45~10:50 ÁúÀÇ ÀÀ´ä ()

ÈÞ½Ä 09¿ù 22ÀÏ 10:50~11:00 ÈÞ½Ä ()

±³À°½Ã°£ 09¿ù 22ÀÏ Room3 11:00~11:25 ü¾×·®°ú ±ÙÀ° °¨¼ÒÁõ °­¼®ÈÖ(¿µ³²ÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room3 11:25~11:50 Hemodiafiltration or Expanded hemodialysis? ÀÓÁ¤ÈÆ(°æºÏÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room3 11:50~12:15 warfarin vs. NOAC ±è¼º±Ô(´ë±¸°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room3 12:15~12:40 ¹Ýº¹µÇ´Â ÆóºÎÁ¾ ȯÀÚ, ¾î¶»°Ô Çϳª¿ä? ¹éÁøÇõ(°è¸íÀÇ´ë)

Åä·Ð 09¿ù 22ÀÏ Room3 12:40~12:50 ÆгÎÅäÀÇ °­°Ç¿ì, ±ÇÇõ¸¸(°¡Å縯 ¿¬ÇÕ³»°ú, ÇÑ°¡¶÷º´¿ø)

½Ä»ç 09¿ù 22ÀÏ 12:50~13:50 ½Ä»ç ()

±³À°½Ã°£ 09¿ù 22ÀÏ Room3 13:50~14:15 Pretransplant heart disease testing and kidney transplant outcomes ±è¼­¸°(ºÎ»êÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room3 14:15~14:40 Emerging evidence on coronary heart disease screening in kidney transplantation candidates Á¤Èñ¿¬(°æºÏÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room3 14:40~15:05 Paradigm shift in lifestyle modification for solitary kidney after donor nephrectomy ¿ÀÁؼ®(±è¿ø¹¬±â³äºÀ»ýº´¿ø)

Åä·Ð 09¿ù 22ÀÏ Room3 15:05~15:20 ½ÅÀÌ½Ä Áõ·Ê Åä·Ð 1 ÀÌÇöÁ¤(°è¸íÀÇ´ë)

Åä·Ð 09¿ù 22ÀÏ Room3 15:20~15:40 ½ÅÀÌ½Ä Áõ·Ê Åä·Ð 2 ¹Úº´È­(°í½ÅÀÇ´ë)

ÈÞ½Ä 09¿ù 22ÀÏ 15:40~15:50 ÈÞ½Ä ()

±³À°½Ã°£ 09¿ù 22ÀÏ Room3 15:50~16:15 PPI associated nephrotoxicity À̽ÂÇý(°æ»óÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room3 16:15~16:40 Acute kidney injury in patients with liver cirrhosis ¹Ú½ÃÇü(ÀÎÁ¦ÀÇ´ë)

±³À°½Ã°£ 09¿ù 22ÀÏ Room3 16:40~17:05 Use of DOAC in hemodialysis patients ¾ÈÁ¤¸í(±è¿ø¹¬±â³ä)

±³À°½Ã°£ 09¿ù 22ÀÏ Room3 17:05~17:30 Nutritional intervention in eldery CKD patients ¾È¿ø¼®(µ¿¾ÆÀÇ´ë)

Åä·Ð 09¿ù 22ÀÏ Room3 17:30~17:40 ÁúÀÇ ÀÀ´ä ()

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѽÅÀåÇÐȸ KSN-IAC(Integrated Academic Conference) 2023 ÅëÇÕÇмú´ëȸ(1ÀÏÂ÷) : 2023-09-22""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¼¼ºê¶õ½ºº´¿ø ¾È°ú ±Ý¿äÁý´ãȸ(IOP fluctuation and Glaucoma) : 2023-09-22
´ÙÀ½±Û ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ °æÀÎÁöȸ Çмúȸ : 2023-09-21
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20925 ÀüºÏ Á¦ 53Â÷ ´ëÇѳëÀκ´ÇÐȸ È£³²Áöȸ ÇмúÁý´äȸ : 2024-07-27 0 37 2024-05-28
20924 ¼­¿ï 2024 Á¦27ȸ ´ëÇѾȸ鼺ÇüÀç°ÇÇÐȸ Ãá°è Çмú´ëȸ : 2024-07-21 0 35 2024-05-28
20923 °æ±â 2024³â ÀÏ»ê¹éº´¿ø Á¤Çü¿Ü°ú ½ÉÆ÷Áö¾ö : 2024-07-21 0 31 2024-05-28
20922 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(2ÀÏÂ÷) : 2024-07-20 0 27 2024-05-28
20921 ¼­¿ï Á¦33Â÷ ´ç´¢º´ ¿¬±¸ ÇÏ°è¿öÅ©¼¥ : 2024-07-20 0 31 2024-05-28
20920 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GU Cancers 2024 : 2024-07-19 0 47 2024-05-28
20919 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(1ÀÏÂ÷) : 2024-07-19 0 17 2024-05-28
20918 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-07-14 0 25 2024-05-28
20917 °æºÏ 2024³â ´ëÇÑ°ñ´Ù°øÁõÇÐȸ ¿µ³² ¿¬¼ö°­Á : 2024-07-14 0 24 2024-05-28
20916 °æ±â ÀÎÁ¦´ëÇб³ ÀÏ»ê¹éº´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-13 0 24 2024-05-28
20915 °æ±â 2024³â ÀÇÁ¤ºÎÀ»Áö´ëÇб³º´¿ø Á¦1ȸ ½Å°æ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2024-07-13 0 22 2024-05-28
20914 ºÎ»ê Á¦6ȸ ºÎ»ê¼º¸ðº´¿ø ¼Ò¾Æû¼Ò³â°ú ½ÉÆ÷Áö¾ö : 2024-07-13 0 20 2024-05-28
20913 ¼­¿ï 2024 ´ëÇѽŰ泻ºÐºñ¿¬±¸È¸ ¿¬¼ö°­Á : 2024-07-13 0 23 2024-05-28
20912 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦3Â÷¿¬¼ö±³À° : 2024-07-11 0 28 2024-05-28
20911 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-08 0 28 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷